Future clinical trials should explore IL-1β inhibitors in combination with targeted therapies in molecularly defined subgroups, which have the potential to pave the way for more personalized and effective treatment strategies in lung cancer, ultimately improving patient outcomes. Here, IL1B is linked to lung carcinoma.